Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation suggests that oligodendrocytes could potentially generate a relatively higher proportion of longer Aβ species, which are more prone to aggregation [28]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“The increased Aβ 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“and, consequently, could be more pathogenic than shorter Aβ species”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [8]
In the citing paper
“Dysregulation of A peptide metabolism is hypothesized to initiate pathogenic cascades that lead to Alzheimer's disease (AD) (Haass and Selkoe, 2007).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Haass and Selkoe, 2007
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“These and other findings led to the formal proposal of a hypothesis of disease in which excessive Aβ accumulation and deposition could trigger a complex downstream cascade that resulted in the symptoms of A”
ResultRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“In a similar manner, breakthrough discoveries of causative genes allowed the subsequent identification of aggregation-prone proteins in disorders such as amyotrophic lateral sclerosis (ALS”
ResultUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“More recently, TDP43 was found to be deposited in tau- and synuclein-negative inclusions in a disorder designated as frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) as well as in AL”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Shortly thereafter, a distinct APP missense mutation was found in a family with early-onset A”
Background
Cited by
Items 501–600 of 1,119
Mori, T., Miyashita, N., Im, W., Feig, M., & Sugita, Y. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.12.032 · Cited by 160
“amyloid peptide (A) in the brain is considered to be the primary element in the pathogenesis of AD [217].”
Debnath, K., Pradhan, N., Singh, B. K., Jana, N. R., & Jana, N. R. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06510 · Cited by 149
Limbocker, R., Chia, S., Ruggeri, F. S., Perni, M., Cascella, R., Heller, G. T., Meisl, G., Mannini, B., Habchi, J., Michaels, T. C. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07699-5 · Cited by 161
Shea, D., Hsu, C.-C., Bi, T. M., Paranjapye, N., Childers, M. C., Cochran, J., Tomberlin, C. P., Wang, L., Paris, D., Zonderman, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820585116 · Cited by 149
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
Hureau, C., & Dorlet, P. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.034 · Cited by 160
New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease
Zlokovic, B. V. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.011 · Cited by 151
Mitochondrial import and degradation of amyloid-β peptide
Pinho, C. M., Teixeira, P. F., & Glaser, E. G. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.02.007 · Cited by 163
Koo, J., Kang, E., Oh, Y.-S., Yang, D.-S., & Cho, J. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.014 · Cited by 165
“The loss of SIRT-1 activitymay reduce ADAM-10 expression and, as a result, increase Aβ production (Kumar et al., 2013; Luis et al., 2009; Haass and Selkoe, 2007).”
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
Sebastian Monasor, L., Müller, S. A., Colombo, A. V., Tanrioever, G., König, J., Roth, S., Liesz, A., Berghofer, A., Piechotta, A., Prestel, M., et al. (2020) · eLife · doi:10.7554/elife.54083 · Cited by 147
Self-citationAli, T., Yoon, G. H., Shah, S. A., Lee, H. Y., & Kim, M. O. (2015) · Scientific Reports · doi:10.1038/srep11708 · Cited by 146
Ma, T., Hoeffer, C. A., Wong, H., Massaad, C. A., Zhou, P., Iadecola, C., Murphy, M. P., Pautler, R. G., & Klann, E. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6566-10.2011 · Cited by 146
“Many lines of evidence indicate that impairment of synaptic plasticity by abnormal accumulation of soluble A occurs before plaque formation and neurodegeneration in AD, lending support to the notion that Alzheimer’s disease is a synaptic failure (Selkoe, 2002; Oddo et al., 2003; Jacobsen et al., 2006; Haass and Selkoe…”
BackgroundResultInfluentialSecretase inhibitors and modulators for Alzheimer’s disease treatment
Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 146
Alzheimer's disease amyloid β-protein and synaptic function
Ondrejcak, T., Klyubin, I., Hu, N.-W., Barry, A. E., Cullen, W. K., & Rowan, M. J. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8091-0 · Cited by 146
“…that certain forms of soluble Ab can trigger synaptic pruning in cultured neurons and brain slices in vitro (Roselli et al. 2005; Shankar et al. 2007) and cause cognitive impairment in the absence of neurodegeneration in animals (Cleary et al. 2005; Lesne et al. 2006; Haass and Selkoe 2007).”
BackgroundDinov, I. D., Heavner, B., Tang, M., Glusman, G., Chard, K., Darcy, M., Madduri, R., Pa, J., Spino, C., Kesselman, C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157077 · Cited by 145
“It is increasingly recognized that these misfolded proteins also have the capacity to spread from cell to cell in a “ prion ” like manner [12].”
BackgroundHaass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145
“Only 3 distinct genes have been identified to harbor disease-causing mutations in dominantly inherited AD [6].”
BackgroundSelf-citationOno, K., Condron, M. M., & Teplow, D. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.086496 · Cited by 145
Kimura, R., Devi, L., & Ohno, M. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06608.x · Cited by 145
“It should be noted that Ab42 is more hydrophobic and more prone to assemble into neurotoxic oligomers and aggregates than Ab40 (McGowan et al. 2005; Haass and Selkoe 2007) and that Ab42 is highly overproduced because of a combination of the multiple FAD mutations in 5XFAD mice (Oakley et al. 2006;…”
Wnt signaling in Alzheimer's disease: Up or down, that is the question
Boonen, R. A. C. M., van Tijn, P., & Živković, D. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.11.003 · Cited by 151
“principal role in pre-symptomatic, early stages of the AD process, before the onset of plaque pathology (Haass and Selkoe, 2007).”
BackgroundRay, R., Juranek, J. K., & Rai, V. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.12.006 · Cited by 156
Aprile, F. A., Sormanni, P., Perni, M., Arosio, P., Linse, S., Knowles, T. P. J., Dobson, C. M., & Vendruscolo, M. (2017) · Science Advances · doi:10.1126/sciadv.1700488 · Cited by 145
Vendruscolo, M., & Fuxreiter, M. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167201 · Cited by 144
Targeting autophagy in neurodegenerative diseases
Vidal, R. L., Matus, S., Bargsted, L., & Hetz, C. A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.002 · Cited by 155
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease
Furst, A. J., Rabinovici, G. D., Rostomian, A. H., Steed, T., Alkalay, A., Racine, C., Miller, B. L., & Jagust, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.011 · Cited by 144
“In addition soluble Aβ oligomers have been implicated to play an important role in synaptic loss in AD (Haass and Selkoe, 2007; Walsh and Selkoe, 2007).”
BackgroundTherapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 153
Smilansky, A., Dangoor, L., Nakdimon, I., Ben-Hail, D., Mizrachi, D., & Shoshan-Barmatz, V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.691493 · Cited by 143
“VDAC1-mediated A Neurotoxicity; a Proposed Mechanism—A debate exists as to whether fibrillar aggregates (amyloid) or soluble oligomers of A are the toxic form (71).”
BackgroundProtein Microgels from Amyloid Fibril Networks
Shimanovich, U., Efimov, I., Mason, T. G., Flagmeier, P., Buell, A. K., Gedanken, A., Linse, S. S., Åkerfeldt, K. S., Dobson, C. M., Weitz, D. A., et al. (2014) · ACS Nano · doi:10.1021/nn504869d · Cited by 150
Vascular Aspects of Cognitive Impairment and Dementia
Wiesmann, M., Kiliaan, A. J., & Claassen, J. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.159 · Cited by 143
Apolipoprotein E Regulates Amyloid Formation within Endosomes of Pigment Cells
van Niel, G., Bergam, P., Di Cicco, A., Hurbain, I., Lo Cicero, A., Dingli, F., Palmulli, R., Fort, C., Potier, M. C., Schurgers, L. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.057 · Cited by 143
“, 2001) that contributes to the release of toxic species into the extracellular space (Haass and Selkoe, 2007).”
BackgroundPapadimitriou, C., Celikkaya, H., Cosacak, M. I., Mashkaryan, V., Bray, L., Bhattarai, P., Brandt, K., Hollak, H., Chen, X., He, S., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.06.005 · Cited by 143
Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?
Bayer, T. A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.007 · Cited by 140
“The efficacy of drugs targeting plaques has been questioned however as plaques may serve as reservoirs of toxic Aβ peptides (Benilova et al., 2012; Haass and Selkoe, 2007; Wirths et al., 2004).”
BackgroundLiu, F., Dong, X., He, L., Middelberg, A. P. J., & Sun, Y. P. (2011) · The Journal of Physical Chemistry B · doi:10.1021/jp202640b · Cited by 144
Self Assembly of Short Aromatic Peptides into Amyloid Fibrils and Related Nanostructures
Gazit, E. (2007) · Prion · doi:10.4161/pri.1.1.4095 · Cited by 155
Kim, J., Yoon, H., Basak, J., & Kim, J. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0248 · Cited by 164
“An increasing line of evidence suggests that accumulation of soluble A may be a key factor of synaptic loss and cognitive impairment (Haass and Selkoe, 2007).”
BackgroundLakshmanan, A., Cheong, D. W., Accardo, A., Fabrizio, E. M. D., Riekel, C., & Hauser, C. A. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217742110 · Cited by 140
“Furthermore, there is growing evidence that early oligomers during the self-assembly process are more pathogenic and toxic compared with mature fibrils (10, 11).”
BackgroundResultα-Synuclein Oligomers Impair Neuronal Microtubule-Kinesin Interplay
Prots, I., Veber, V., Brey, S., Campioni, S., Buder, K., Riek, R., Böhm, K. J., & Winner, B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.451815 · Cited by 140
Identification of MOAG-4/SERF as a regulator of age-related proteotoxicity
van Ham, T. J., Holmberg, M. A., van der Goot, A. T., Teuling, E., Garcia-Arencibia, M., Kim, H.-E., Du, D., Thijssen, K. L., Wiersma, M., Burggraaff, R., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.020 · Cited by 133
“…the aggregates were initially thought to be pathogenic, more recent studies suggest that they have a protective role (Arrasate et al., 2004; Nagai et al., 2007; Sanchez et al., 2003; Saudou et al., 1998; Schaffar et al., 2004; Caughey and Lansbury, 2003; Haass and Selkoe, 2007; Kayed et al., 2003).”
BackgroundPalmitoylation in Alzheimers disease and other neurodegenerative diseases
Cho, E., & Park, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.008 · Cited by 138
Lee, M.-C., Yu, W.-C., Shih, Y.-H., Chen, C.-Y., Guo, Z.-H., Huang, S.-J., Chan, J. C. C., & Chen, Y.-R. (2018) · Scientific Reports · doi:10.1038/s41598-018-23122-x · Cited by 134
Mardpour, S., Hamidieh, A. A., Taleahmad, S., Sharifzad, F., Taghikhani, A., & Baharvand, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27669 · Cited by 140
“Degrading misfolded proteins or pathogenic aggregated peptides which are causative agents for cardiomyopathies and Alzheimer’s disease, is one of numerous functions of these functional circulating protea- somes (Haass & Selkoe, 2007; Lai et al., 2012).”
BackgroundArad, E., Green, H., Jelinek, R., & Rapaport, H. (2020) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.03.075 · Cited by 141
Prion protein facilitates uptake of zinc into neuronal cells
Watt, N. T., Taylor, D. R., Kerrigan, T. L., Griffiths, H. H., Rushworth, J. V., Whitehouse, I. J., & Hooper, N. M. (2012) · Nature Communications · doi:10.1038/ncomms2135 · Cited by 139
Seeded strain‐like transmission of β‐amyloid morphotypes in APP transgenic mice
Heilbronner, G., Eisele, Y. S., Langer, F., Kaeser, S. A., Novotny, R., Nagarathinam, A., Åslund, A., Hammarström, P., Nilsson, K. P. R., & Jucker, M. (2013) · EMBO reports · doi:10.1038/embor.2013.137 · Cited by 139
“The most prominent Ab species are full-length or N-truncated Abx-40 (Ab40) and Abx-42 (Ab42) with Ab42 being much more prone to aggregation and more neurotoxic compared with Ab40 [4,5].”
In vitro prion-like behaviour of TDP-43 in ALS
Smethurst, P., Newcombe, J., Troakes, C., Simone, R., Chen, Y.-R., Patani, R., & Sidle, K. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.007 · Cited by 139
“…how prions cause toxicity, however one hypothesis states that they may do so through the development of toxic oligomers (Sandberg et al., 2014; Sandberg et al., 2011) similar to that proposed with beta amyloid in Alzheimer's disease (Haass and Selkoe, 2007; Umeda et al., 2015; Wilcox et al., 2011).”
BackgroundResultZawisza, I. A., Rózga, M., & Bal, W. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.012 · Cited by 149
Membrane injury by pore-forming proteins
Bischofberger, M., Gonzalez, M. R., & van der Goot, F. G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.04.003 · Cited by 143
“Following the hypothesis that amyloid proteins can form pore-like intermediates, it has been proposed that the fibrillar deposits actually constitute a defense mechanism to sequester the deadly intermediate structures [61].”
BackgroundBruno, O., Fedele, E., Prickaerts, J., Parker, L., Canepa, E., Brullo, C., Cavallero, A., Gardella, E., Balbi, A., Domenicotti, C., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01524.x · Cited by 137
Research Progress in the Pathogenesis of Alzheimer's Disease
Chen, Y.-G. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.235112 · Cited by 136
“Even so, accumulational soluble Aβ oligomer can damage synaptic junction and generate neurovirulence.[9] In pathology situation, the unbalance between the production and clearance rate of Aβ can lead to its sedimentation, causing for AD to happen using tau protein poisonousness, destroying intracellular calcium homeos…”
BackgroundThird generation antibody discovery methods:in silico rational design
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00523k · Cited by 135
Morel, B., Varela, L., Azuaga, A. I., & Conejero‐Lara, F. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.10.039 · Cited by 140
“Biophysical Journal 99(11) 3801–3810 in the size distributions (Fig.”
BackgroundInfluentialProtective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase
Atamna, H., & Kumar, R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100414 · Cited by 136
“The most accepted view for the pathological mechanism of AD is the accumulation of small peptides known as amyloid-β (Aβ) in the brains of AD patients [1].”
Fused in sarcoma (FUS): An oncogene goes awry in neurodegeneration
Dormann, D., & Haass, C. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.03.006 · Cited by 159
“006 inclusions provided tremendous insights into the underlying disease mechanisms (Haass and Selkoe, 2007).”
BackgroundSelf-citationPaula-Lima, A. C., Adasme, T., SanMartín, C., Sebollela, A., Hetz, C., Carrasco, M. A., Ferreira, S. T., & Hidalgo, C. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3287 · Cited by 136
“Numerous reports have linked the pathogenesis of AD, the most frequent cause of dementia worldwide, with the accumulation and aggregation of amyloid beta (Ab)-peptide in the brain (27, 46); for a review, see (29).”
Despa, S., Margulies, K. B., Chen, L., Knowlton, A. A., Havel, P. J., Taegtmeyer, H., Bers, D. M., & Despa, F. (2012) · Circulation Research · doi:10.1161/circresaha.111.258285 · Cited by 137
“37 Similarly, -amyloid oligomers induce neuron dysfunction and death in Alzheimer disease through a mechanism involving increased [Ca(2) ]i.(20,24,25) Thus, we examined Ca 2 cycling in cardiac myocytes incubated with exogenous amylin oligomers.”
Analyzing Amyloid Beta Aggregates with a Combinatorial Fluorescent Molecular Sensor
Hatai, J., Motiei, L., & Margulies, D. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b10809 · Cited by 137
Lerdkrai, C., Asavapanumas, N., Brawek, B., Kovalchuk, Y., Mojtahedi, N., Olmedillas del Moral, M., & Garaschuk, O. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714409115 · Cited by 137
“At the same time, accumulation of amyloid β species may also cause neuronal silencing (58, 59), creating an uneven distribution of hyperactive cells throughout the brain (14, 15).”
BackgroundAmyloid-β and Parkinson’s disease
Kings Parcog groupMDS Nonmotor study group, Lim, E. W., Aarsland, D., Ffytche, D. H., Taddei, R. N., van Wamelen, D. J., Wan, Y.-M., Tan, E. K., & Chaudhuri, К. R. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9100-8 · Cited by 157
Is Alzheimer’s a disease of the white matter?
Sachdev, P. S., Zhuang, L., Braidy, N., & Wen, W. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835ed6e8 · Cited by 137
“The amyloid cascade model, which posits the Ab peptide as the major cause of synaptic and neuronal loss in gray matter, has been well accepted as a fundamental mechanism of pathogenesis of Alzheimer’s disease [50,51].”
BackgroundAmyloid-β Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain
Lasagna-Reeves, C. A., Glabe, C. G., & Kayed, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.236257 · Cited by 136
The role of histone acetylation in age-associated memory impairment and Alzheimer’s disease
Stilling, R. M., & Fischer, A. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.04.002 · Cited by 136
Hossain, M. F., Uddin, M. S., Uddin, G. M. S., Sumsuzzman, D. M., Islam, M. S., Barreto, G. E., Mathew, B., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01660-3 · Cited by 138
The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity
Sharma, A. K., Pavlova, S. T., Kim, J., Kim, J., & Mirica, L. M. (2013) · Metallomics · doi:10.1039/c3mt00161j · Cited by 150
Qin, X.-Y., Cao, C., Cawley, N. X., Liu, T.-T., Yuan, J., Loh, Y. P., & Cheng, Y. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.62 · Cited by 142
Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine
Anekonda, T. S., & Quinn, J. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.013 · Cited by 134
“Soluble intraneuronal Aβ oligomers, soluble and insoluble Aβ fibrils can increase intracellular Ca2+, impair neuronal function, and adversely affect synaptic functions in AD [13, 22, 23].”
BackgroundSite-Specific Blockade of RAGE-VdPrevents Amyloid-β Oligomer Neurotoxicity
Sturchler, E., Galichet, A., Weibel, M., Leclerc, E., & Heizmann, C. W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4878-07.2008 · Cited by 136
“At the current stage of research, we cannot conclude that large insoluble aggregates, fibrils, or soluble oligomers represent the sole molecular pathogen in AD; indeed, various A species may play relevant roles in neurotoxicity (Haass and Selkoe, 2007).”
BackgroundMicroglia in Alzheimer’s disease: A multifaceted relationship
ElAli, A., & Rivest, S. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.07.021 · Cited by 134
“…of Aβ peptides, namely Aβ1–40 and Aβ1–42, triggers a sustained and chronic inflammatory response, tau hyperphosphorylation, synaptotoxicity and consequently neuronal loss, thus leading to the progressive cognitive decline (Jack et al., 2013; Hardy and Selkoe, 2002; Haass and Selkoe, 2007).”
BackgroundAmyloid Aggregation on Lipid Bilayers and Its Impact on Membrane Permeability
Friedman, R., Pellarin, R., & Caflisch, A. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.12.036 · Cited by 135
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li, Q., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.006 · Cited by 134
“Currently, amyloid b (Ab) is widely regarded as the principal hallmark of AD [2].”
BackgroundJansen, C., Parchi, P., Capellari, S., Vermeij, A. J., Corrado, P., Baas, F., Strammiello, R., van Gool, W. A., van Swieten, J. C., & Rozemuller, A. J. M. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0609-x · Cited by 134
“These findings suggest a relationship between amyloid fibrils and the formation of abnormal tau deposits, irrespective of the chemical type of amyloid, possibly contradicting the hypothesis that monomeric molecules, such as Ab, are the direct cause of tau accumulations [ 14 ].”
ResultPramanik, D., Ghosh, C., & Dey, S. G. (2011) · Journal of the American Chemical Society · doi:10.1021/ja204628b · Cited by 133
Kostylev, M. A., Kaufman, A. C., Nygaard, H. B., Patel, P., Haas, L. T., Gunther, E. C., Vortmeyer, A., & Strittmatter, S. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.643577 · Cited by 133
“Pinpointing the key ADmediating A o assemblies, resolving their properties, biochemical origin, and mechanism of downstream action are the key challenges of the amyloid hypothesis (10, 20, 79).”
BackgroundThe endocytic pathway in microglia during health, aging and Alzheimer’s disease
Solé-Domènech, S., Cruz, D. L., Capetillo-Zarate, E., & Maxfield, F. R. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.07.002 · Cited by 133
Praet, J., Manyakov, N. V., Muchene, L., Mai, Z., Terzopoulos, V., de Backer, S., Torremans, A., Guns, P.-J., Van De Casteele, T., Bottelbergs, A., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0329-8 · Cited by 133
“The latter are known to be highly toxic to neuronal synapses and will result in synaptic loss [8].”
BackgroundQuantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer’s disease
Xiong, F., Ge, W., & Ma, C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.006 · Cited by 133
“on behalf of the Alzheimer’s Assoc accepted that APs are dynamic and serve as a reservoir of various forms of Ab and other bioactive molecules [5].”
BackgroundHamilton, A., Esseltine, J. L., DeVries, R. A., Cregan, S. P., & Ferguson, S. S. G. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-40 · Cited by 133
“The degeneration of glutamatergic synapses is associated with disrupted neuronal signaling and synaptic loss has traditionally been associated with alterations in ionotropic NMDA and AMPA receptor signaling [3,42-44].”
BackgroundJung, K.-M., Astarita, G., Yasar, S., Vasilevko, V., Cribbs, D. H., Head, E., Cotman, C. W., & Piomelli, D. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.012 · Cited by 133
“…levels of anandamide correlate with the patients’ performance in cognitive tests of psychomotor speed and linguistic ability, but not with amyloid plaque burden or tau-protein hyperphosphorylation, two features of AD neuropathology that are linked to neuronal cell death (Haass and Selkoe, 2007).”
BackgroundHellwig, K., Kvartsberg, H., Portelius, E., Andreasson, U., Oberstein, T. J., Lewczuk, P., Blennow, K., Kornhuber, J., Maler, J. M., Zetterberg, H., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0161-y · Cited by 132
Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer’s disease
Ma, T., & Klann, E. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07506.x · Cited by 132
Carrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arévalo-Serrano, J., & Gonzalo-Ruiz, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.004 · Cited by 132
The amyloid cascade hypothesis
Korczyn, A. D. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.11.008 · Cited by 132
“It underwent everal transformations, initially assuming a direct effect of he amyloid plaque on neighboring neurons, until its present ersion suggesting a toxic role of soluble oligomers [2].”
BackgroundRAS–MAPK–MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1
Park, J., Al-Ramahi, I., Tan, Q., Mollema, N., Diaz-Garcia, J. R., Gallego-Flores, T., Lu, H.-C., Lagalwar, S., Duvick, L., Kang, H., et al. (2013) · Nature · doi:10.1038/nature12204 · Cited by 132
Islet amyloid polypeptide demonstrates a persistent capacity to disrupt membrane integrity
Last, N. B., Rhoades, E. R., & Miranker, A. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102356108 · Cited by 248
“Instead, it has been suggested that cell dysfunction and death are mediated by small oligomeric species that acquire the capacity to disrupt cellular membrane integrity (3, 4).”
BackgroundAmyloid-beta transporter expression at the blood-CSF barrier is age-dependent
Pascale, C. L., Miller, M. C., Chiu, C., Boylan, M., Caralopoulos, I. N., Gonzalez, L., Johanson, C. E., & Silverberg, G. D. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-21 · Cited by 132
“Increased amyloid burden in the AD brain is neurotoxic and leads to neuritic plaque formation, chronic inflammation and neuronal death [2,31].”
Mechanisms and Function of Dendritic Exocytosis
Kennedy, M. J., & Ehlers, M. D. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.032 · Cited by 132
Pathways and Intermediates of Amyloid Fibril Formation
Pellarin, R., Guarnera, E., & Caflisch, A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.09.090 · Cited by 136
“soluble oligomers and protofibrils, have a critical role in promoting pathological effects in amyloid disorders.(3,4) As an example, the E22G mutation of the Alzheimer's peptide (Aβ) enhances protofibril formation,(5) and plaque formation is more aggressive than for wildtype Aβ in transgenic mice.”
BackgroundNakamura, T., Cieplak, P., Cho, D.-H., Godzik, A., & Lipton, S. A. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.04.007 · Cited by 131
“Recently, several lines of evidence have suggested that soluble oligomers of Aβ represent the most toxic form of the peptide (Haass and Selkoe, 2007).”
BackgroundMacrocyclic β-Sheet Peptides That Inhibit the Aggregation of a Tau-Protein-Derived Hexapeptide
Zheng, J., Liu, C., Sawaya, M. R., Balraju, V., Khan, S., Woods, R. J., Eisenberg, D. S., Goux, W. J., & Nowick, J. S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja110545h · Cited by 145
Conserved features of intermediates in amyloid assembly determine their benign or toxic states
Krishnan, R., Goodman, J. L., Mukhopadhyay, S., Pacheco, C. D., Lemke, E. A., Deniz, A. A., & Lindquist, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209527109 · Cited by 131
“As proteins assemble into amyloid, they populate transient oligomeric intermediates (8).”
BackgroundExploring the aggregation free energy landscape of the amyloid-β protein (1–40)
Zheng, W., Tsai, M., Chen, M., & Wolynes, P. G. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612362113 · Cited by 135
Itkin, A., Duprès, V., Dufrêne, Y. F., Bechinger, B., Ruysschaert, J., & Raussens, V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018250 · Cited by 145
“Although comparable in length (9506460 nm, n = 20) to previously reported fibril lengths [54], they were too thin to be categorized as fibrils.”
BackgroundResultRinauro, D. J., Chiti, F., Vendruscolo, M., & Limbocker, R. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00651-2 · Cited by 150
“Well before these achievements, the hypothesis that small oligomers, as opposed to fibrils, are the main pathogenic species in AD had been supported by many lines of circumstantial evidence [1, 100, 102, 103].”
ResultPujadas, L., Rossi, D., Andrés, R., Teixeira, C. M., Serra-Vidal, B., Parcerisas, A., Maldonado, R., Giralt, E., Carulla, N., & Soriano, E. (2014) · Nature Communications · doi:10.1038/ncomms4443 · Cited by 129
Devi, L., Alldred, M. J., Ginsberg, S. D., & Ohno, M. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-34 · Cited by 129
“Our results clearly demonstrated that 5-day exposure to restraint stress increased levels of Ab42 peptides, a pathogenic Ab species that is more hydrophobic and has the propensity to assemble into neurotoxic oligomers and aggregates [33-35], in the hippocampus of female 5XFAD mice but not in male 5XFAD mice.”
ResultUnfolded protein response‐induced ERdj3 secretion links ER stress to extracellular proteostasis
Genereux, J. C., Qu, S., Zhou, M., Ryno, L. M., Wang, S., Shoulders, M. D., Kaufman, R. J., Lasmézas, C. I., Kelly, J. W., & Wiseman, R. L. (2014) · The EMBO Journal · doi:10.15252/embj.201488896 · Cited by 145
“Protein disulfide isomerases (PDIs) can also be secreted to promote extracellular disulfide exchange (Jordan & Gibbins, 2006; Hahm et al , 2013).”
Sequestration of a β‐Hairpin for Control of α‐Synuclein Aggregation
Mirecka, E. A., Shaykhalishahi, H., Gauhar, A., Akgül, Ş., Lecher, J., Willbold, D., Stoldt, M., & Hoyer, W. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309001 · Cited by 127
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer’s disease
Kam, T.-I., Song, S., Gwon, Y., Park, H., Yan, J.-J., Im, I., Choi, J.-W., Choi, T.-Y., Kim, J., Song, D.-K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66827 · Cited by 128
“Because the synaptic dysfunction evoked by Aβ provides a molecular and cellular basis for memory deficits and neuropathological features of dementia in AD (38, 39), we investigated the role of FcγRIIb in learning and memory deficits using an AD mouse model.”
van Wijk, N., Broersen, L. M., de Wilde, M. C., Hageman, R. J. J., Groenendijk, M., Sijben, J. W. C., & Kamphuis, P. J. G. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130998 · Cited by 128
“A accumulation is considered an upstream event in the cascade that leads to synaptic loss and synaptic dysfunction [4, 8–10].”
microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain
Kim, J., Yoon, H., Horie, T., Burchett, J. M., Restivo, J. L., Rotllan, N., Ramírez, C. M., Verghese, P. B., Ihara, M., Hoe, H.-S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2053-15.2015 · Cited by 137
“Dysregulation of A peptide metabolism is hypothesized to initiate pathogenic cascades that lead to Alzheimer’s disease (AD) (Haass and Selkoe, 2007).”
BackgroundLu, Y., Ferris, J., & Gao, F.-B. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-30 · Cited by 128
“In many neurodegenerative diseases, defects in synaptic connections are probably one of the earliest alterations preceding neurodegeneration [34].”
BackgroundThe pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease
Belkouch, M., Hachem, M., Elgot, A., Van, A. L., Picq, M., Guichardant, M., Lagarde, M., & Bernoud‐Hubac, N. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.03.002 · Cited by 134
“Soluble Aβ oligomers (AβO) are described as the most neurotoxic/synaptotoxic subspecies in AD neuropathology as compared to fibrillar species [4,5].”
Background
Metadata
- Authors
- Haass, C., & Selkoe, D. J.
- Affiliations
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 101-112
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W1980825524
- Cited by
- 4,744
- References
- 135
- Citations by year
- 2026: 135 · 2025: 171 · 2024: 165 · 2023: 170 · 2022: 195 · 2021: 239 · 2020: 273 · 2019: 247 · 2018: 276 · 2017: 290 · 2016: 331 · 2015: 313 · 2014: 285 · 2013: 307 · 2012: 327
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neurodegeneration, protein misfolding, protein aggregation, synaptic dysfunction, synaptic plasticity, Parkinson's disease, Huntington's disease, prion disease, neuronal dysfunction
- MeSH terms
- Alzheimer Disease, Cell Membrane, Humans, Memory Disorders, Models, Biological, Nerve Degeneration, Solubility, Synapses, Signal Transduction, Amyloid beta-Peptides, Protein Folding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.